Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922880 · ClinicalTrials.gov registry record · Phase 1
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
A Phase 1 study of Uveal Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03922880 is a Phase 1 study of Uveal Melanoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03922880, a Phase 1 study of Uveal Melanoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG ADI PEG20
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922880
The ClinicalTrials.gov registry entry for NCT03922880 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (94% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT03922880 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03922880 about?
NCT03922880 is a clinical study titled "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma". This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma.
What is the current status of trial NCT03922880?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-04-16. Estimated completion is 2023-01-20.
What conditions does trial NCT03922880 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT03922880?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), ADI PEG20 (DRUG).
Who is sponsoring clinical trial NCT03922880?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922880 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
RECRUITING · Phase 1
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.